|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM277185750 |
| 003 |
DE-627 |
| 005 |
20250222115538.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.issn.0578-1310.2017.10.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0923.xml
|
| 035 |
|
|
|a (DE-627)NLM277185750
|
| 035 |
|
|
|a (NLM)29050112
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Huang, S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.02.2018
|
| 500 |
|
|
|a Date Revised 02.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To review the clinical-pathology characteristics of 19 relapsed pediatric mature B cell lymphoma and to find the risk factors for recurrence and the feasible treatment after relapse. Method: Data of 212 pediatric B cell lymphomas cases in Beijing Children's Hospital from January 2006 to June 2015 were collected retrospectively. All the patients were treated according to the B cell lymphoma regimen of Beijing Children's Hospital. During the study period, 19 of 212 cases were relapsed; the clinio-pathological characteristics of relapsed patients before treatment and after relapse were analyzed retrospectively, the treatment outcomes after relapse were summarized and the patients were followed-up. Result: Nineteen of 212 cases had relapsed disease, for these relapsed patients: the median age at initial diagnosis was 5.5 years old, the median level of uric acid was 384(range, 121-713)μmol/L, the median level of lactate dehydrogenase(LDH) was 1 323(range, 146-6 370)U/L. Among 19 relapsed patients, 10 had local relapse and 9 had multiple relapses; 17 were Burkitt's lymphoma and 2 were diffuse large B cell lymphoma. Staging: 2 cases were stageⅡ, 3 cases were stage Ⅲ and 14 cases were stage Ⅳ. Risk group: 6 cases were group B and 13 cases were group C. Nine cases had bone marrow involvement and 10 cases had central nervous system(CNS) involvement. Acute tumor lysis syndrome was seen in 6 cases during the early treatment and 13 cases had delayed treatment. Treatment after relapse: 10 cases received further treatment after relapse (rituximab + 1-4 courses high intensity second-line chemotherapy), 3 cases received autologous stem cell transplantation. There was no chemotherapy or infection related death, 3 cases achieved complete remission (CR). For all the 212 patients, the median follow-up time was 47 (range, 1-131)months and the 5-year event free survival(EFS)rate was (89.4±0.2)%. For the 19 relapse cases, the 5-year overall survival (OS) rate was (21.1±0.1)%, CR rate after relapse was 30%, patients died of the progression of the primary disease, no treatment related death occurred. Univariate analyses showed that bulky disease, stage Ⅳ, maxillofacial and CNS involvement, LDH>1 000 U/L, delay treatment, day 7 evaluation shrink <25%, residual diseases after 3 months treatment are relapse risk factors (all P<0.01). Conclusion: Patients relapse during the treatment or at the early stage after the end of all chemotherapy have poor prognosis. So far there is no effective method for early relapse patients; the late relapse patients had the possibility of CR if they are sensitive to salvage treatment. In conclusion, to improve the outcome, the key point is to reduce the relapse
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Child
|
| 650 |
|
4 |
|a Lymphoma, B-Cell
|
| 650 |
|
4 |
|a Prognosis
|
| 650 |
|
4 |
|a Recurrence
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
| 700 |
1 |
|
|a Jin, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Duan, Y L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, C J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, X L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Y H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 55(2017), 10 vom: 02. Okt., Seite 748-753
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:55
|g year:2017
|g number:10
|g day:02
|g month:10
|g pages:748-753
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2017.10.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 55
|j 2017
|e 10
|b 02
|c 10
|h 748-753
|